Literature DB >> 19178883

Thyroid arterial embolization for the treatment of hyperthyroidism in a patient with thyrotoxic crisis.

Wei Zhao1, Bu-Lang Gao, Gen-Fa Yi, Hui-Ying Yang, Hong Li.   

Abstract

PURPOSE: We report a case of hyperthyroidism in a young woman caused by Graves' disease that was successfully treated with thyroid arterial embolization. CLINICAL DETAILS: A 35 year-old woman with a history of thyrotoxic crises was admitted after the last thyroid crisis. Thyroid arterial embolization was used to treat the hyperthyroidism after it had been controlled. Immediately after embolization, the enlarged thyroid gland shrank and vascular murmurs disappeared. Serum thyroid hormones increased on day 3 following embolization but decreased gradually. Thyroid hormone returned to normal 2 months after embolization and remained normal at three years.
CONCLUSION: Thyroid arterial embolization is an effective means to treat refractory hyperthyroidism.

Entities:  

Mesh:

Year:  2009        PMID: 19178883     DOI: 10.25011/cim.v32i1.5091

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  3 in total

1.  Thyroid arterial embolization in a patient with congenital heart disease and refractory amiodarone-induced thyrotoxicosis.

Authors:  Bruno Bouça; Ana Cláudia Martins; Paula Bogalho; Lídia Sousa; Tiago Bilhim; Filipe Veloso Gomes; Élia Coimbra; Ana Agapito; José Silva-Nunes
Journal:  Eur Thyroid J       Date:  2022-01-01

2.  Evaluation of selective embolization of thyroid arteries (SETA) as a preresective treatment in selected cases of toxic goitre.

Authors:  Marek Dedecjus; Józef Tazbir; Zbigniew Kaurzel; Grzegorz Strózyk; Arkadiusz Zygmunt; Andrzej Lewiński; Jan Brzeziński
Journal:  Thyroid Res       Date:  2009-07-31

3.  The calcium-phosphate balance, modulation of thyroid autoimmune processes and other adverse effects connected with thyroid arterial embolization.

Authors:  Grzegorz Kaminski; Andrzej Jaroszuk; Ariadna Zybek; Krzysztof Brzozowski; Piotr Piasecki; Piotr Ziecina; Marek Ruchala
Journal:  Endocrine       Date:  2013-10-22       Impact factor: 3.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.